Adding SGLT2 Cotransporter Inhibitor to PPARγ Activator Does Not Provide an Additive Effect in the Management of Diabetes-Induced Vascular Dysfunction
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adding SGLT2 Cotransporter Inhibitor to PPARγ Activator Does Not Provide an Additive Effect in the Management of Diabetes-Induced Vascular Dysfunction
Authors
Keywords
-
Journal
PHARMACOLOGY
Volume -, Issue -, Pages 1-11
Publisher
S. Karger AG
Online
2023-10-17
DOI
10.1159/000533592
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
- (2022) Charlotte C. van Ruiten et al. Cardiovascular Diabetology
- Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
- (2021) Lorenzo Nesti et al. Cardiovascular Diabetology
- Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors
- (2021) Husam Ghanim et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus
- (2021) Eva Kralova et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
- (2021) Manasvi Gupta et al. Therapeutics and Clinical Risk Management
- Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
- (2021) Teresa Salvatore et al. Biomedicines
- Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
- (2020) Byambasuren Ganbaatar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Early Endothelial Dysfunction in Type 1 Diabetes Is Accompanied by an Impairment of Vascular Smooth Muscle Function: A Meta-Analysis
- (2020) Elodie Lespagnol et al. Frontiers in Endocrinology
- SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
- (2019) Anastasios Tentolouris et al. International Journal of Environmental Research and Public Health
- SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
- (2018) Dustin M. Lee et al. Cardiovascular Diabetology
- The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
- (2018) Hongliang Li et al. LIFE SCIENCES
- Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
- (2018) Mahmoud El-Daly et al. VASCULAR PHARMACOLOGY
- Resveratrol prevents cognitive deficits by attenuating oxidative damage and inflammation in rat model of streptozotocin diabetes induced vascular dementia
- (2018) Semil Selcen Gocmez et al. PHYSIOLOGY & BEHAVIOR
- Quercetin and pioglitazone synergistically reverse endothelial dysfunction in isolated aorta from fructose-streptozotocin (F-STZ)-induced diabetic rats
- (2017) Thubasni Kunasegaran et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Endothelial NADPH oxidases: which NOX to target in vascular disease?
- (2014) Grant R. Drummond et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Rosmarinic acid administration attenuates diabetes-induced vascular dysfunction of the rat aorta
- (2013) Ruzena Sotnikova et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets?
- (2013) Luc Rochette et al. PHARMACOLOGY & THERAPEUTICS
- Oxidative stress in vascular disease and its pharmacological prevention
- (2013) Huige Li et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction
- (2012) Jian Ye et al. BMC BIOINFORMATICS
- Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders
- (2012) Pitchai Balakumar et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance
- (2012) Valentina Spigoni et al. PLoS One
- Effects of Pioglitazone and Rosiglitazone on Vascular Function of Mesenteric Resistance Arteries in Rat Genetic Hypertension
- (2011) Yolanda Mendizábal et al. PHARMACOLOGY
- Oxidative stress modulates PPARγ in vascular endothelial cells
- (2010) Carmelo Blanquicett et al. FREE RADICAL BIOLOGY AND MEDICINE
- Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells
- (2010) Ming-Jui Hung et al. JOURNAL OF HYPERTENSION
- A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS
- (2010) Chris R. Triggle et al. Journal of the American Society of Hypertension
- Endothelial Dysfunction, Inflammation, and Apoptosis in Diabetes Mellitus
- (2010) Inge A. M. van den Oever et al. MEDIATORS OF INFLAMMATION
- Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes
- (2008) Sudarshan K. Vijay et al. ACTA DIABETOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More